Evidence map›Paper›PMID 41859772›Full record

SynthesisEndocrinology, diabetes & metabolism2026

Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta-Analyses of Randomised Controlled Trials.

Vali Musazadeh, Maryam Falahatzadeh, Mahsa Mahmoudinezhad, Erfan Shahhooseini, Mehrdad Jamali, Pedram Pam, Farzad Shidfar

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vali MusazadehStudent Research Committee, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-4978-9474
Maryam FalahatzadehDepartment of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0009-0005-8139-8392
Mahsa MahmoudinezhadStudent Research Committee, Urmia University of Medical Sciences, Urmia, Iran.ORCID https://orcid.org/0000-0002-9267-8438
Erfan ShahhooseiniTehran University of Medical Sciences, Tehran, Iran.
Mehrdad JamaliStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0009-0005-6518-5362
Pedram PamDepartment of Nutrition, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.ORCID https://orcid.org/0009-0008-3856-0595
Farzad ShidfarDepartment of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-6531-9253

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral meta-analyses suggest that Coenzyme Q10 (CoQ10) supplementation is associated with glycemic control; however, findings about fasting blood glucose (FBG) and haemoglobin A1c (HbA1c) remain inconsistent across studies. Accordingly, this study aimed to synthesise the results to present a firm conclusion in relation to the efficacy of CoQ10 on glycemic control.

methodsA systematic search was conducted to find meta-analyses of randomised controlled trials using PubMed, Scopus, Web of Science and the Cochrane Database of Systematic Reviews from inception to March 6, 2025. Also, the methodological quality of included studies was evaluated using the AMSTAR2 tool.

resultsIn total, eight meta-analyses were included in this umbrella systematic review and meta-analysis. Pooled analysis using standardized mean difference analysis demonstrated that CoQ10 is associated with decreased FBG. While it didn't exert any significant changes on the HbA1c, HOMA-IR, and insulin levels. In addition, the combined effect of CoQ10 using weighted mean difference analysis revealed that CoQ10 is able to decrease the FBG (5.04 mg/dL), HbA1c (0.17%), HOMA-IR (0.72), and insulin (1.32 μIU/mL) levels significantly.

conclusionThe present study suggests that CoQ10 supplementation may have a moderate beneficial effect on glycemic control in diabetic patients, though findings differ depending on analytic approach.

Indexed as

Blood GlucoseDietary SupplementsGlycemic ControlUbiquinoneBiomarkersGlycated HemoglobinHumansMeta-Analysis as TopicRandomized Controlled Trials as TopicBiomarkersBlood Glucosecoenzyme Q10Glycated Hemoglobinhemoglobin A1c protein, humanUbiquinoneCoQ10glycemic indicesinsulinrandomised controlled trialstype 2 diabetesumbrella meta‐analysis

Identifiers

PMID41859772
PMCPMC13093519

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.